Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Acquisitions & Divestments (2020 - 2025)

Historic Change in Acquisitions & Divestments for Kymera Therapeutics (KYMR) over the last 6 years, with Q3 2025 value amounting to $132.4 million.

  • Kymera Therapeutics' Change in Acquisitions & Divestments fell 408.11% to $132.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $532.1 million, marking a year-over-year increase of 2143.8%. This contributed to the annual value of $510.0 million for FY2024, which is 4029.25% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Change in Acquisitions & Divestments stood at $132.4 million, which was down 408.11% from $119.0 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Change in Acquisitions & Divestments ranged from a high of $147.9 million in Q4 2024 and a low of $60.5 million during Q1 2021
  • Over the past 5 years, Kymera Therapeutics' median Change in Acquisitions & Divestments value was $106.5 million (recorded in 2022), while the average stood at $109.7 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Change in Acquisitions & Divestments surged by 49073.51% in 2021, and later crashed by 3259.69% in 2023.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Change in Acquisitions & Divestments stood at $96.9 million in 2021, then grew by 1.1% to $97.9 million in 2022, then decreased by 22.32% to $76.1 million in 2023, then soared by 94.43% to $147.9 million in 2024, then decreased by 10.47% to $132.4 million in 2025.
  • Its Change in Acquisitions & Divestments was $132.4 million in Q3 2025, compared to $119.0 million in Q2 2025 and $132.7 million in Q1 2025.